Elegen is a pioneering company in the synthetic biology sector, focused on revolutionizing the DNA synthesis process with an innovative approach that achieves an industry-leading length of 7kb in just 7 business days, boasting an impressive 99.999% accuracy per base. Founded and led by Dr. Matthew Hill in San Carlos, CA, Elegen is backed by prominent life science investors and staffed by top-tier biotechnology scientists and entrepreneurs. The company aims to address critical bottlenecks in synthetic biology workflows for customers in pharma, biotech, agbio, and biomanufacturing, thereby unlocking the full potential of programmable biology. With recent funding and strategic partnerships, Elegen is positioned to disrupt the synthetic DNA supply market and is committed to fostering a culture of respect, integrity, and collaboration within its rapidly growing team.